Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Novavax stock fell 6% as it revised revenue guidance. With their COVID-19 vaccine as their main product, Novavax aims to boost market share through a deal with Sanofi and licensing its adjuvant to other pharma companies, focusing on product pipeline and restarting vaccine trials.